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Abstract
Background: Deregulated miRNAs are found in cancer cells and recently in blood cells of cancer
patients. Due to their inherent stability miRNAs may offer themselves for blood based tumor
diagnosis. Here we addressed the question whether there is a sufficient number of miRNAs
deregulated in blood cells of cancer patients to be able to distinguish between cancer patients and
controls.
Methods: We synthesized 866 human miRNAs and miRNA star sequences as annotated in the
Sanger miRBase onto a microarray designed by febit biomed gmbh. Using the fully automated
Geniom Real Time Analyzer platform, we analyzed the miRNA expression in 17 blood cell samples
of patients with non-small cell lung carcinomas (NSCLC) and in 19 blood samples of healthy
controls.
Results: Using t-test, we detected 27 miRNAs significantly deregulated in blood cells of lung
cancer patients as compared to the controls. Some of these miRNAs were validated using qRT-
PCR. To estimate the value of each deregulated miRNA, we grouped all miRNAs according to their
diagnostic information that was measured by Mutual Information. Using a subset of 24 miRNAs, a
radial basis function Support Vector Machine allowed for discriminating between blood cellsamples
of tumor patients and controls with an accuracy of 95.4% [94.9%-95.9%], a specificity of 98.1%
[97.3%-98.8%], and a sensitivity of 92.5% [91.8%-92.5%].
Conclusion: Our findings support the idea that neoplasia may lead to a deregulation of miRNA
expression in blood cells of cancer patients compared to blood cells of healthy individuals.
Furthermore, we provide evidence that miRNA patterns can be used to detect human cancers
from blood cells.
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Background
Lung cancer is the leading cause of cancer death world-
wide [1]. Its five-year survival rate is among the lowest of
all cancer types and is markedly correlated to the stage at
the time of diagnosis [2]. Using currently existing tech-
niques, more than two-thirds of lung cancers are diag-
nosed at late stages, when the relative survival rate is low
[3]. This reality calls for the search of new biomarkers that
are able to catch lung cancer while it is still small and
locally defined.
MicroRNAs (miRNA) are a recently discovered class of
small non-coding RNAs (17-24 nucleotides) [4]. Due to
their function as regulators of gene expression they play a
critical role both in physiological and in pathological
processes, such as cancer [5-8]. This fact is also outlined by
the "Human MiRNAs & Diseases" database, the most
comprehensive resource on the web, containing hundreds
of entries showing the deregulation of miRNAs in a man-
ifold of human diseases [9].
There is increasing evidence that microRNAs are not only
found in tissues but also in human blood cells both as free
circulating nucleic acids and in mononuclear cells. A
recent proof-of-principle study demonstrated miRNA
expression pattern in pooled blood sera and pooled blood
cells, both in healthy individuals and in cancer patients
including patients with lung cancer [10]. In addition, a
remarkable stability of miRNAs in human sera was
recently demonstrated [10,11]. These findings make
miRNA a potential tool for a cancer diagnostics based on
blood analysis. Since single biomarkers usually lack suffi-
cient specificity and sensitivity, we set out to analyze com-
plex miRNA expression pattern in blood cells of cancer
patients. We synthesized 866 human miRNAs and miRNA
star sequences as annotated in the Sanger miRBase
([12,13], Version 12.0) on a microarray designed by febit
biomed gmbh. This array combined with the fully auto-
mated Geniom Real Time Analyzer (GRTA) platform
allows for measuring miRNA fingerprints and ensures a
high degree of reproducibility. To identify miRNA expres-
sion pattern we analyzed the expression of 866 miRNAs in
17 blood samples of patients with non-small cell lung car-
cinomas and in 19 blood samples of healthy controls.
The aim of our study was to address the following ques-
tions: Is there a larger number of differentially regulated
miRNAs in blood cells of lung cancer patients as com-
pared to healthy controls? To what extend do miRNA
expression profiles in blood cells allow for the discrimina-
tion of lung cancer patients from controls? What is the
information content of single miRNAs for such discrimi-
nation? Does the platform used in these experiments offer
the option of a highly reproducible and efficient large-
scale diagnostic test? The answers to these questions will
also lay the ground for the analysis of blood based miRNA
expression profiles in other cancers.
Methods
Samples
The analysis of blood from lung cancer patients and
healthy subjects has been approved by local ethics com-
mittee and participants have given written informed con-
sent. Blood samples were obtained with patients'
informed consent. The patient samples stem from 17
patients with non-small cell lung carcinoma and normal
controls. Normal samples were obtained from 19 differ-
ent volunteers. More detailed information of patients and
controls is given in Tables 1 and 2.
miRNA extraction and microarray screening
Blood of lung cancer patients and volunteers without
known disease was extracted in PAXgene Blood RNA tubes
(BD, Franklin Lakes, New Jersey USA). For each blood
donor, 5 ml of peripheral blood were obtained. The con-
tent of blood sampling tubes of each patient and healthy
donor was centrifuged at 5000 g for 10 min at room tem-
perature. The supernatant was discarded while the pellet
was resuspended in 10 ml RNase free water by vortex. The
suspension is again centrifuged at 5000 g for 10 min at RT.
Subsequently, the total RNA including the miRNA was
isolated using the miRNeasy kit (Qiagen GmbH, Hilden).
Therefore the pellet was resuspended in 700 μl QIAzol
lysis reagent and incubated for 5 min at RT. Then, 140 μl
chloroform were added, vortexed for 15 sec, and incu-
bated for 2-3 min at RT. This was followed by a centrifu-
gation at 14000 rpm and 4°C for 15 min. The upper,
watery phase was removed and 1,5 times of its volume
added in 100% ethanol (ca. 900 μl). Each 700 μl of this
mixture were placed on a column and centrifuged at
13000 rpm at RT for 15 sec. After the mixture had com-
pletely passed the column, 700 μl of Buffer RWT were
added to each column, and again centrifuged at 13000
rpm at RT for 15 sec. Following this, 500 μl Buffer RPL
were added to the column and centrifuged at 13000 rpm
at RT for 15 sec. After this, another 500 μl Buffer RPL were
added to the column and centrifuged at 13000 rpm at RT
for 2 min. The column was then centrifuged at 13000 rpm
Table 1: Information on lung cancer patients and healthy control 
subjects
blood donors male female
lung cancer patients
number 9 8
average age 67 61
healthy subjects
number 7 12
average age 43 35BMC Cancer 2009, 9:353 http://www.biomedcentral.com/1471-2407/9/353
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and RT for 1 min to dry it. The following was the elution
step with 40 μl RNase free water, centrifuging at 13000
rpm at RT for 1 min. The eluted RNA was stored at -70°C.
Samples were analyzed with the Geniom Realtime Ana-
lyzer (GRTA, febit gmbh, Heidelberg, Germany) using the
Geniom Biochip miRNA homo sapiens. Each array con-
tains 7 replicates of 866 miRNAs and miRNA star
sequences as annotated in the Sanger miRBase 12.0
[13,14]. Sample labeling with Biotine has been carried out
either by using the miRVANA™ miRNA Labeling Kit
(Applied Biosystems Inc, Foster City, California USA) or
by microfluidic-based enzymatic on-chip labeling of miR-
NAs (MPEA [15]).
Following hybridization for 16 hours at 42°C the biochip
was washed automatically and a program for signal
enhancement was processed with the GRTA. The resulting
detection pictures were evaluated using the Geniom Wiz-
ard Software. For each array, the median signal intensity
was extracted from the raw data file such that for each
miRNA seven intensity values have been calculated corre-
sponding to each replicate copy of miRBase on the array.
Following background correction, the seven replicate
intensity values of each miRNA were summarized by their
median value. To normalize the data across different
arrays, quantile normalization [16] was applied and all
further analyses were carried out using the normalized
and background subtracted intensity values.
We stored all microarray data in the miRDBXP (manu-
script in preparation), a database which is designed to
store any type of microRNA expression pattern. The data-
base is freely accessible at http://64.119.137.93/fmi/iwp.
In addition, the data are also available in GEO
(GSE17681).
Statistical analysis
After having verified the normal distribution of the meas-
ured data, we carried out parametric t-test (unpaired, two-
tailed) for each miRNA separately, to detect miRNAs that
show a different behavior in different groups of blood
donors. The resulting p-values were adjusted for multiple
testing by Benjamini-Hochberg [17,18] adjustment.
Moreover, the Mutual Information (MI) [19] was com-
puted as a measure to access the diagnostic value of single
miRNA biomarkers. To this end, all biomarkers were
transformed to z-scores and binned in three bins before
the MI values of each biomarker, and the information
whether the marker has been measured from a normal or
lung cancer sample, was computed. In addition to the sin-
gle biomarker analysis classification of samples using
miRNA patterns was carried out using Support Vector
Machines (SVM, [20]) as implemented in the R [21]
e1071 package. In detail, different kernel (linear, polyno-
mial, sigmoid, radial basis function) Support Vector
Machines have been evaluated, where the cost parameter
was sampled from 0.01 to 10 in decimal powers. The
measured miRNA profiles were classified using 100 repe-
titions of standard 10-fold cross-validation. As a subset
selection technique we applied a filter approach based on
t-test. In detail, the s miRNAs with lowest p-values were
computed on the training set in each fold of the cross val-
idation, where s was sampled from 1 to 866. The respec-
tive subset was used to train the SVM and to carry out the
prediction of the test samples. As result, the mean accu-
racy, specificity, and sensitivity were calculated together
with the 95% Confidence Intervals (95% CI) for each sub-
set size. To check for overtraining we applied permutation
tests. Here we sampled the class labels randomly and car-
ried out classifications using the permuted class labels. All
statistical analyzes were performed using R [21-23].
Results
miRNA experiments
We analyzed the expression of 866 miRNAs and miRNA
star sequences in blood cells of 17 patients with NSCLC.
As a control we used blood cells of 19 volunteers without
known disease (see also Materials and Methods).
Following RNA isolation and labeling by miRVANA™
miRNA Labeling Kit, the miRNA expression profiles were
measured by the Geniom Bioship miRNA homo sapiens
in the GRTA (febit gmbh, Heidelberg). Following inten-
sity value computation and quantile normalization of the
miRNA profiles [16], we determined a mean correlation
value of 0.97 for technical replicates by using purchased
total RNA from Ambion (four heart and four liver repli-
cates). As comparison, we computed the mean correlation
Table 2: Staging of patients and tumor type
sample tumor type clinical stage
463 adenocarcinoma T2N0
464 typical carcinoid T2N0
468 adenocarcinoma T2N0
469 adenocarcinoma T2N2
485 adenocarcinoma T2N0
490 adeno squamous carcinoma T2N0
492 adenocarcinoma T2N0
503 squamous cell carcinoma T1N0
507 squamous cell carcinoma T4Nx
508 squamous cell carcinoma T2aN0
509 squamous cell carcinoma T2N0
513 bronchoalveolar carcinoma T3N0
514 adenocarcinoma T2N2
517 squamous cell carcinoma T2N0
523 squamous cell carcinoma T2N0
524 squamous cell carcinoma T3N2
525 adenocarcinoma T1N0BMC Cancer 2009, 9:353 http://www.biomedcentral.com/1471-2407/9/353
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of all cancer samples with all other cancer samples and all
normal samples with all other normal samples. Here, we
still reached a high correlation of 0.87 and a variance of
0.009.
ruling out the influence of age and gender
To cross-check that age and gender do not have an influ-
ence on our analysis, we computed t-tests for the normal
samples. In the case of males versus females we did not
find any statistically significant deregulated miRNA. The
most significant miRNA, hsa-miR-423, showed an
adjusted significance level of 0.78.
To test for the influence of donor age we compared the
profiles obtained from samples obtains from the oldest
versus youngest patients by splitting the group in half
based on age. Here the most significant miRNA, miR-890,
obtained an adjusted p-value of 0.87. As for gender, we
did not find any deregulated miRNAs, thus providing evi-
dence that age and gender do not have a substantial influ-
ence on the miRNA profiles.
single deregulated miRNAs
We applied hypothesis testing to identify miRNAs deregu-
lated in the blood cells of lung cancer patients as com-
pared to the blood cells of the controls. Following
verification of an approximately normal distribution, we
performed two-tailed unpaired t-tests for each miRNA.
The respective p-values were adjusted for multiple testing
by the Benjamini-Hochberg approach [17,18]. In total we
detected 27 miRNAs significantly deregulated in blood
cells of lung cancer patients as compared to the controls.
A complete list of deregulated miRNAs is given in the Sup-
plemental Material (see Additional file 1 - Table S1). The
miRNAs that were most significantly deregulated included
hsa-miR-126 with a p-value of 0.00003, hsa-let-7d with a
p-value of 0.003, hsa-let-7i with a p-value of 0.003, and
hsa-miR-423 with a p-value of 0.001 (Figure 1 and Figure
2). Other members of the let-7 family that were also
The bar-chart shows for 15 of the 27 deregulated miRNAs the median value of cancer samples and normal samples Figure 1
The bar-chart shows for 15 of the 27 deregulated miRNAs the median value of cancer samples and normal 
samples. Here, blue bars correspond to cancer samples while red bars to controls.BMC Cancer 2009, 9:353 http://www.biomedcentral.com/1471-2407/9/353
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Back to back histograms of two examples Figure 2
Back to back histograms of two examples. The color-coding corresponds to the one used in Figure 1.
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Scatterplot of fold quotients of qRT-PCR (x-axis) and microarray experiments (y-axis) Figure 3
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found to be deregulated included hsa-let-7c, hsa-let-7e,
hsa-let-7f, hsa-let-7g and hsa-let-7a. Besides miR-423, all
above mentioned miRNAs were down-regulated in blood
cells of lung cancer patients compared to blood cells of
healthy subjects indicating an overall decreased miRNA
repertoire.
To validate our findings, we repeated the miRNA profiling
using an enzymatic on-chip labeling technique termed
MPEA (Microfluidic-based enzymatic on-chip labeling of
miRNAs) [24]. For this control experiment, we used 4 out
of the 17 lung cancer patients and 10 of the controls.
Hereby, we detected 100 differentially regulated miRNAs.
The miRNAs that were most significantly deregulated
include hsa-miR-1253 with a p-value of 0.001, hsa-miR-
126 with a p-value of 0.006, hsa-let-7d with a p-value of
0.006, and hsa-let-7f with a p-value of 0.006. Of the pre-
viously identified 27 miRNAs 12 were detected to be sig-
nificant in the second experiment, while the remaining
miRNAs showed increased p-values. The correlation of
fold changes was 0.62. We also confirmed other members
of the let-7 family as deregulated in blood cells of lung
cancer patients. Furthermore, we confirmed that the
majority of the deregulated miRNAs were down-regulated
in patients' blood cells. In these Experiments, 62% of the
significantly deregulated miRNAs showed decreased
intensity values in lung cancer samples. In the Supple-
mental Material we provide a complete list of deregulated
miRNAs identified by MPEA (see Additional file 1 - Table
S1).
As a further control experiment we performed an expres-
sion analysis by qRT-PCR. As a test sample we analyzed
the fold changes of hsa-miR-106b, miR-162, miR-98,
miR-let7d, miR-22, and miR-140-3p in blood cells of
eight tumor patients and five controls. Of these 6 miR-
NAs, 3 belong to the group of 12 miRNAs significant for
miRVANA labeling and the MPEA method. The result of
this validation experiment was a verification of the micro-
array screening. For example, in agreement with the up-
regulation detected by the Geniom Biochip experiments,
the qRT-PCR experiments showed on average an up-regu-
lation of 1.4 fold in blood cells of lung cancer patients as
compared to healthy controls for miR 106b. The excellent
correlation of microarray and qRT-PCR data is demon-
strated by an R2 value of 0.994 (see Figure 3).
Diagnostic value of miRNA biomarkers
Mutual Information (MI) [19] is an adequate measure to
estimate the overall diagnostic information content of sin-
gle biomarkers [22]. In our study, Mutual Information is
considered as the reduction in uncertainty about the class
The mutual information of all miRNAs that have higher information content than the best permutation test (upper red line) Figure 4
The mutual information of all miRNAs that have higher information content than the best permutation test 
(upper red line). The middle red line denotes the 95% quantile of the 1000 permutation tests and the bottom red line the 
mean of the permutation experiments, corresponding to the background MI.BMC Cancer 2009, 9:353 http://www.biomedcentral.com/1471-2407/9/353
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labels '0' for controls and '1' for tumor samples due to the
knowledge of the miRNA expression. The higher the value
of the MI of a miRNA, the higher is the diagnostic content
of the respective miRNA.
We computed the MI of each miRNA with the class labels.
First, we carried out a permutation test to determine the
background noise of the miRNAs, e.g. the random infor-
mation content of each miRNA. We randomly selected
1000 miRNAs (with replacements) and sampled the class
labels for each miRNA. These permutation tests yielded a
mean MI value of 0.029, a 95% quantile of 0.096 and a
value of 0.217 for the highest random MI. Second, we cal-
culated the MI values for the comparison between the
miRNAs in blood cells of tumor patients and controls. The
overall comparison of the 866 miRNAs yielded signifi-
cantly increased MI values with a two-tailed p-value of ≤
10-10 as shown by an unpaired Wilcoxon Mann-Whitney
test [23,24]. The miRNA hsa-miR-361-5p showed the
highest MI with a value of 0.446. The miRNAs with the
best significance values as computed by the t-test, namely
hsa-miR-126 and hsa-miR-98, were also among the miR-
NAs showing the highest MI values. In total we detected
37 miRNAs with MI values higher than the highest of
1000 permuted miRNAs and 200 miRNAs with MI values
higher than the 95% quantile (Figure 4). Of the initially
detected 27 miRNAs by the t-test, 14 had values higher
than the highest permutation test and all remaining 13
miRNAs belong to the group of miRNAs with MI values
higher than the 95% quantile, demonstrating the overall
well agreement of the two measures. Venn diagrams for
the different analyses are provided as Venn diagrams (Fig-
ures 5A and 5B). A complete list of miRNAs, the respective
MI and the enrichment compared to the background MI is
provided in the supplemental material (see Additional file
2 - Table S2).
Evaluating complex fingerprints
Even single miRNAs with highest MI values are not suffi-
cient to differentiate between blood cells of tumor
patients as compared to controls with high specificity. For
example, the hsa-miR-126 separates blood cells of tumor
patients from blood cells of healthy individuals with a
specificity of 68%, only. In order to improve the classifica-
tion accuracy we combined the predictive power of multi-
ple miRNAs by using statistical learning techniques. In
detail, we applied Support Vector Machines with different
kernels (linear, polynomial, sigmoid, radial basis func-
tion) to the data and carried out a hypothesis test based
subset selection as described in Material and Methods. To
gain statistical significance we carried out 100 repetitions
of 10-fold cross validation. Likewise, we computed 100
repetitions for the permutation tests.
The best results were obtained with radial basis function
Support Vector Machines and a subset of 24 miRNAs
(Table 3 and Venn Diagram in Figure 5C). These miRNAs
allowed for the discrimination between blood cells of
lung tumor patients and blood cells of controls with an
accuracy of 95.4% [94.9%-95.9%], a specificity of 98.1%
[97.3%-98.8%], and a sensitivity of 92.5% [91.8%-
92.5%]. The permutation tests showed significantly
decreased accuracy, specificity, and sensitivity with 49.2%
Venn diagrams for different analyses Figure 5
Venn diagrams for different analyses. A) Venn diagram 
of the t-test mirVANA and MPEA labeling. B) Venn diagram 
of the t-test and the Mutual Information. The right circle 
shows significant MI miRNAs, separated in the miRNAs that 
are higher than the highest permutation test and the miRNAs 
higher than 95% of all 1000 permutation tests. The 27 miR-
NAs are all included in these miRNAs, indicated by the green 
circle. C) Venn diagram of t-test miRNAs and miRNAs used 
in the best classification subset. The 24 miRNAs used for 
classification are all contained in the set of 27 most significant 
mRNAsBMC Cancer 2009, 9:353 http://www.biomedcentral.com/1471-2407/9/353
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[47.2%-51.3%], 56.9% [54.5%-59.3%] and 40.6%
[37.9%-43.4%], respectively (Figure 6), providing evi-
dence that the obtained results are not due to an overfit of
the statistical model on the miRNA fingerprints.
Discussion
While complex miRNA expression patterns have been
reported for a huge variety of human tumors, far less
information is available on miRNA expression patterns of
blood cells derived from tumor patients. In the following
we relate our miRNA expression profiling to both the
miRNA expression in blood cells and in cancer cells of
non-small cell lung cancer patients. We found significant
down-regulation of hsa-miR-126 that was recently
detected in blood cells of healthy individuals, but not in
blood cells of lung cancer patients [10]. Down-regulation
of hsa-miR-126 was also found in lung cancer tissue [25].
Functional studies on hsa-miR-126 revealed this miRNA
as a regulator of the endothelial expression of vascular cell
adhesion molecule 1 (VCAM-1), which is an intercellular
adhesion molecule expressed by endothelial cells [26].
hsa-miR-126 is also reported to be an inhibitor of cell
invasion in non-small cell lung cancer cell lines, and
down-regulation of this miRNA might be a mechanism of
lung cancer cells to evade these inhibitory effects [27].
Members of the hsa-let-7 family that were found down-
regulated in our study were the first miRNAs reported as
de-regulated in lung cancer [28]. This down-regulation of
the let-7 family in lung cancer was confirmed by several
Table 3: miRNAs that are in the best subset
miRNA median cancer median control Fold change Log(FC) t-test adj
hsa-miR-126 606,46 3428,42 0,18 -1,73 3,43E-05
hsa-miR-423-5p 6795,89 3976,97 1,71 0,54 0,000978034
hsa-let-7d 6795,89 13307,74 0,51 -0,67 0,002715951
hsa-let-7i 4106,11 6349,31 0,65 -0,44 0,002715951
hsa-miR-15a 3428,42 5944,79 0,58 -0,55 0,008784487
hsa-miR-22 7978,5 3868,5 2,06 0,72 0,008784487
hsa-miR-98 322,44 1440,75 0,22 -1,5 0,008784487
hsa-miR-19a 420,06 1 420,06 6,04 0,015204977
hsa-miR-20b 1118,35 2947,83 0,38 -0,97 0,015204977
hsa-miR-324-3p 1221,94 700,5 1,74 0,56 0,015204977
hsa-miR-574-5p 108,56 30,22 3,59 1,28 0,015204977
hsa-miR-195 2575,72 4462,58 0,58 -0,55 0,018313065
hsa-miR-25 12517,64 7639,53 1,64 0,49 0,018313065
hsa-let-7e 1297,51 2947,83 0,44 -0,82 0,019691385
hsa-let-7c 5660,31 8969,72 0,63 -0,46 0,019946719
hsa-let-7f 5382,15 9746,17 0,55 -0,59 0,019992878
hsa-let-7a 6795,89 12517,64 0,54 -0,61 0,022999135
hsa-let-7g 3428,42 6795,89 0,5 -0,68 0,023591848
hsa-miR-140-3p 9312,5 4621,29 2,02 0,7 0,024644601
hsa-miR-339-5p 312,11 12,44 25,08 3,22 0,025550318
hsa-miR-361-5p 606,46 53 11,44 2,44 0,030845953
hsa-miR-1283 2,33 22,22 0,11 -2,25 0,03712987
hsa-miR-18a* 1040,44 119,89 8,68 2,16 0,04393972
hsa-miR-26b 1085,22 2058,85 0,53 -0,64 0,044122011
Boxplots of the classification accuracy, specificity, and sensi- tivity of the 100 repetitions of the 10-fold cross-validation  (red boxes) and the same values for random permutation  tests (blue boxes) Figure 6
Boxplots of the classification accuracy, specificity, 
and sensitivity of the 100 repetitions of the 10-fold 
cross-validation (red boxes) and the same values for 
random permutation tests (blue boxes).BMC Cancer 2009, 9:353 http://www.biomedcentral.com/1471-2407/9/353
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independent studies [29-33]. Our data are also in agree-
ment with a recent study showing the down-regulation of
hsa-let-7a, hsa-let-7d, hsa-let-7f, hsa-let-7g, and hsa-let-7i
in blood cells of lung cancer patients [10]. Notably, down-
regulation of let-7 in lung cancer was strongly associated
with poor clinical outcome [29]. The let-7 family mem-
bers negatively regulate oncogene RAS [28]. The miRNA
hsa-miR-22 that showed a high MI value and up-regula-
tion in our study, was recently also reported to be up-reg-
ulated in blood cells of lung cancer patients [10]. The
miRNA hsa-miR-19a that also showed a high MI value
and up-regulation in our study was reported to be up-reg-
ulated in lung cancer tissue [34,35]. In contrast, hsa-miR-
20a, which is significantly down-regulated in our experi-
ments, was reported as up-regulated in lung cancer tissue
[34,35]. The up-regulation of hsa-miR-20a was found in
small-cell lung cancer cell lines, our study investigated
only NSCLC. In summary, there is a high degree of con-
sistency between miRNA expression found in the periph-
eral blood cells of lung cancer patients and miRNA
expression in lung cancer tissue [25,29-37].
Some of the deregulated miRNAs identified in our study
are also reported as de-regulated in other cancer entities,
e.g. hsa-miR-346 in gastritic cancer, hsa-miR-145 in blad-
der cancer, and hsa-miR-19a in hepatocellular carcinoma
and B-cell leukemia [38-42]. We also found miRNAs with
high diagnostic potential e.g. high MI value, that were not
yet related to cancer as for example hsa-miR-527 or hsa-
mir-361-5p that were both up-regulated in blood cells of
lung cancer patients.
Besides the deregulation of single miRNAs, we analyzed
the overall expression pattern of miRNAs in peripheral
blood cells of lung cancer patients in comparison to the
pattern in blood cells of healthy controls. Recently, Chen
et al. [10] reported a high correlation of 0.9205 between
miRNA profiles in serum and miRNA profiles in blood
cells, both in healthy individuals. The correlation of the
miRNA profiles between serum and blood cells in lung
cancer patients were significantly lower (0.4492). These
results are indicative of deregulated miRNAs in blood
and/or serum of patients and are in agreement with our
data that show the deregulation of miRNAs in the blood
cells of lung carcinoma patients. These deregulated miR-
NAs can be used to differentiate patients with lung cancer
from normal controls with high specificity and sensitivity.
Conclusion
This is the first evidence for the diagnostic potential of
miRNA expression profiles in peripheral blood cells of
cancer patients and healthy individuals. It remains to be
seen whether other cancers and other non-cancer diseases
also show a specific miRNA expression pattern that might
be used to tell these diseases apart form controls and pos-
sibly apart from each other.
We are optimistic that the high specificity and sensitivity
of the miRNAs deregulated in blood cells of lung carci-
noma patients together with the high reproducibility of
the applied technique will open avenues for applying this
approach in prospective trials of a non-invasive diagnostic
test.
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